trials
Novartis report longest median OS in breast cancer study
June 3, 2021Novartis, breast cancer, trials
Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …
Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
AMAG Pharmaceuticals’ shares fall 21% after failed Makena trial
March 11, 2019Sales and Marketing AMAG Pharmaceuticals, Makena, PROLONG, birth, trials
AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …
OxyContin drugmaker Purdue Pharma exploring bankruptcy, sources say
March 4, 2019Manufacturing and Production Litigation, Purdue Pharma, bankruptcy, opioid crisis, trials
OxyContin drugmaker Purdue Pharma is exploring the option of filing for bankruptcy. The news comes as the Connecticut-based firm faces …
Stem cells could ‘reset’ immune system in Crohn’s disease patients
August 8, 2018Research and Development Crohn’s disease, Stem cells, crohn's disease, trials
A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s …
First-in-man Zika vaccine trials get green light
June 21, 2016Manufacturing and Production, Research and Development trials, zika vaccine
Inovio Pharmaceuticals (NASDAQ: INO) and GeneOne Life Science (KSE: 011000) have announced that approval has been granted for the commencement …
Drug development contracts: can lessons be learned from healthcare delivery?
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, CRO, Les Rose, NHS, drug development, trials
There is a very good question to ask at the beginning of every project: “What does success look like?” If …
Servier slammed over UK trial transparency failure
September 8, 2014Medical Communications, Research and Development, Sales and Marketing ABPI, PMCPA, Servier, code, conduct, transparancy, trials
Servier has been found guilty of the most serious breach of the UK’s pharma code of conduct after failing to …
Lilly the latest to open up data
June 4, 2014Medical Communications, Research and Development, Sales and Marketing Goldacre, NHS, alltrials, data, lilly, transparency, trials
Eli Lilly is to begin sharing its clinical trial data with scientific researchers through a website housing information from several …
EMA launches speedy pilot
March 21, 2014Sales and Marketing BIA, EMA, MHRA, NICE, early access, trials
The European Medicines Agency (EMA) has launched an initiative aimed at speeding up the drug approval process and wants help …
Look beyond the screen
March 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, cliinical, data, screening, trials
It makes sense, doesn’t it? You have a drug that’s effective for a certain disease, but no patients. What do …
Unpublished trials ‘violates ethical obligation’ to patients
October 30, 2013Research and Development, Sales and Marketing BMJ, Goldacre, all trials, trials
A new study published in the BMJ has found almost one in three (29%) of large clinical trials remain unpublished …
Grant NICE greater trial data access – report
May 29, 2013Research and Development, Sales and Marketing Goldacre, NICE, transparency, trials
A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …
Novartis R&D warning
November 29, 2012Research and Development, Sales and Marketing NHS, Novartis. R&D, trials
Novartis has hit out at what it sees as the high cost of UK clinical trials, warning that business will …
EFPIA rejects ‘indiscriminate’ transparency
November 16, 2012Medical Communications, Research and Development, Sales and Marketing EFPIA, Goldacre, transparency, trials
Europe’s pharma trade body has poured tepid water on the idea of open access to clinical trial data, saying that …
